Reference health
Management of Pulmonary Arterial Hypertension
1 of 106 checkable references need attention · checked 2026-08-10
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1007/978-3-662-45805-1_9
The 105 checked references that resolve
resolves10.1093/eurheartj/ehp297
Guidelines for the diagnosis and treatment of pulmonary hypertension
resolves10.1183/09031936.00145608
Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review
resolves10.1164/rccm.200602-165OC
High Frequency of
<i>BMPR2</i>
Exonic Deletions/Duplications in Familial Pulmonary Arterial Hypertension
resolves10.1136/jmg.37.10.741
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family
resolves10.1136/jmg.40.12.865
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia
resolves10.1161/CIRCGENETICS.111.961888
Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension
resolves10.1183/09031936.00104807
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
resolves10.1161/CIRCULATIONAHA.111.079921
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
resolves10.1183/09031936.00057914
Pulmonary arterial hypertension in patients treated with interferon
resolves10.1002/art.30541
Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long‐term survival
resolves10.1136/annrheumdis-2013-203301
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
resolves10.1164/rccm.200704-541OC
Prevalence of HIV-Related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era
resolves10.1378/chest.11-1460
An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry
resolves10.1136/hrt.2006.098848
Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease
resolves10.1161/CIRCULATIONAHA.108.803221
Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis
resolves10.1016/j.jacc.2010.03.065
Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension
resolves10.1378/chest.11-0483
The Role of Target Therapies in Schistosomiasis-Associated Pulmonary Arterial Hypertension
resolves10.1038/ng.2844
EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension
resolves10.1016/j.jacc.2004.02.029
Cellular and molecular pathobiology of pulmonary arterial hypertension
resolves10.1016/j.jacc.2013.10.025
Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
resolves10.1161/CIRCRESAHA.113.301141
Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension
resolves10.1161/CIRCULATIONAHA.113.004555
Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
resolves10.1183/09031936.00151313
Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension
resolves10.7326/0003-4819-105-4-499
Primary Pulmonary Hypertension: Radiographic and Scintigraphic Patterns of Histologic Subtypes
resolves10.1161/CIRCULATIONAHA.109.911818
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
resolves10.1183/09031936.00004414
Validation of two predictive models for survival in pulmonary arterial hypertension
resolves10.1016/j.echo.2010.05.010
Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography
resolves10.1016/j.jacc.2006.07.061
Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
resolves10.1161/CIRCULATIONAHA.104.488486
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
resolves10.1161/CIRCHEARTFAILURE.109.930701
Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
resolves10.1161/CIRCHEARTFAILURE.110.958801
Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction
resolves10.1016/j.echo.2007.10.003
Noninvasive Differentiation of Pulmonary Arterial and Venous Hypertension Using Conventional and Doppler Tissue Imaging Echocardiography
resolves10.1016/j.jcmg.2013.05.014
LA Volume by CMR Distinguishes Idiopathic From Pulmonary Hypertension Due to HFpEF
resolves10.1161/CIRCULATIONAHA.106.618397
Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension
resolves10.1056/NEJM199207093270203
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
resolves10.1378/chest.112.3.714
The Effect of Anticoagulant Therapy in Primary and Anorectic Drug-Induced Pulmonary Hypertension
resolves10.1161/01.CIR.70.4.580
Primary pulmonary hypertension: natural history and the importance of thrombosis.
resolves10.1161/CIRCULATIONAHA.113.004526
Anticoagulation and Survival in Pulmonary Arterial Hypertension
resolves10.1164/ajrccm.159.6.9804054
Prostacyclin Synthase Expression Is Decreased in Lungs from Patients with Severe Pulmonary Hypertension
resolves10.1056/NEJM199602013340504
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
resolves10.1016/S0735-1097(02)02012-0
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
resolves10.7326/0003-4819-132-6-200003210-00002
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
resolves10.1164/ajrccm.165.6.2106079
Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial
resolves10.1016/j.jacc.2010.01.027
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
resolves10.1161/CIRCULATIONAHA.112.124388
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension
resolves10.1378/chest.11-2212
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study)
resolves10.1378/chest.12-2875
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study)
resolves10.7326/0003-4819-114-6-464
Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease?
resolves10.1056/NEJM199306173282402
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
resolves10.1016/S0140-6736(08)60919-8
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
resolves10.1161/CIRCULATIONAHA.107.742510
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
resolves10.1056/NEJMoa1213917
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
resolves10.1056/NEJM199507273330403
Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension
resolves10.1183/09031936.00039808
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension
resolves10.1161/CIRCULATIONAHA.110.981738
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
resolves10.1056/NEJMoa1209657
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
resolves10.1164/rccm.201104-0662CI
Intensive Care Unit Management of Patients with Severe Pulmonary Hypertension and Right Heart Failure
resolves10.1016/j.ejcts.2010.02.039
Long-term outcome of double-lung and heart–lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients☆
resolves10.1161/CIRCULATIONAHA.114.006974
Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
resolves10.1183/09031936.00072210
Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension
resolves10.1183/09031936.00116313
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
resolves10.1183/09031936.00137511
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
resolves10.1161/CIRCULATIONAHA.112.000765
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension
resolves10.1161/CIRCULATIONAHA.105.591321
Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension
resolves10.1253/circj.CJ-13-0443
Double-Blind, Placebo-Controlled Clinical Trial With a Rho-Kinase Inhibitor in Pulmonary Arterial Hypertension
resolves10.1002/art.23303
Immunosuppressive therapy in lupus‐ and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty‐three cases
resolves10.1161/hc0202.101974
Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats
resolves10.1172/JCI65592
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension
resolves10.1016/j.jacc.2006.12.037
Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension
resolves10.1164/rccm.201203-0411OC
Dysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension
resolves10.1164/rccm.201003-0335OC
Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats
resolves10.1016/j.jacc.2013.05.075
Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension
resolves10.1093/ejcts/ezu445
Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients
resolves10.1016/j.healun.2013.01.1049
Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience
resolves10.1183/09031936.00089212
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey
resolves10.1183/09031936.00141211
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era
resolves10.1016/j.athoracsur.2012.10.013
Use of the Impella 2.5 Microaxial Pump for Right Ventricular Support After Insertion of Heartmate II Left Ventricular Assist Device
resolves10.1001/jamainternmed.2013.319
Referral of Patients With Pulmonary Hypertension Diagnoses to Tertiary Pulmonary Hypertension Centers
The 5 references without a DOI — listed, not checked
no DOI — not checkedAminorex and pulmonary hypertension. A review
no DOI — not checkedMcLaughlin VV. Effect of selexipag on morbidity/mortality in pulmonary arterial hyertension: results of the GRIPHON study. Paper presented at: ACC.15; March 15, 2015; San Diego, CA.
no DOI — not checkedClinicalTrials.gov. Rituximab for treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01086540. Accessed March 15, 2015.
no DOI — not checkedClinicalTrials.gov. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01083524. Accessed March 15, 2015.
no DOI — not checkedUse of Tandem Heart as a temporary hemodynamic support option for severe pulmonary artery hypertension complicated by cardiogenic shock
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-10 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.jacc.2015.03.540"><img src="https://citestamp.com/citestamped/10.1016/j.jacc.2015.03.540/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.jacc.2015.03.540)